Biological Bone Markers and Hydrolyzed Collagen Supplement in Menopausal Healthy Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01293045 |
Recruitment Status :
Completed
First Posted : February 10, 2011
Last Update Posted : April 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
- Preliminary scientific studies, in both animals and humans suggest that oral consumption of hydrolyzed collagen acts on the bone remodeling process by stimulating the activity of osteoblasts responsible for bone formation while improving the bone mineral density and biomechanical resistance of long bones.
- The objective of this clinical research is to measure changes in biomarkers of bone turnover in postmenopausal healthy women, not osteoporotic, in response to consumption of hydrolyzed collagen for three months.
- For this, we propose to measure blood and urinary markers of formation and bone resorption before consumption, then 45 and 90 days after daily consumption of 10 g of hydrolyzed collagen.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoporosis | Dietary Supplement: hydrolyzed collagen Dietary Supplement: wheat protein | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 44 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Official Title: | Study of Change in Biological Markers of Bone Metabolism Following Consumption of Hydrolyzed Collagen for 3 Months in Healthy, Non-osteoporotic, Menopausal Women. |
Study Start Date : | June 2010 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: HC Group
Group of volunteers fed with Hydrolyzed Collagen
|
Dietary Supplement: hydrolyzed collagen
10g/day at breakfast during 90 days |
Active Comparator: CT Group
Group of volunteers fed with wheat proteins
|
Dietary Supplement: wheat protein
10g/day at breakfast during 90 days |
- Serum C-terminal telopeptide of type 1 collagen (CTX) [ Time Frame: Day 45 ]MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in serum CTX at 45 days
- Urinary telopeptide N-terminal of type 1 collagen (NTX) [ Time Frame: Day 45 ]MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in urinary NTX at 45 days
- Serum osteocalcin [ Time Frame: Day 45 ]MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum osteocalcin at 45 days
- Serum bone alkaline phosphatase [ Time Frame: Day 45 ]MARKERS OF BONE FORMATION: change from Baseline (Day 0) in serum bone alkaline phosphatase at 45 days
- Serum amino-terminal pro-peptide of type 1 procollagen (P1NP) [ Time Frame: Day 45 ]MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum P1NP at 45 days
- Urinary telopeptide N-terminal of type 1 collagen (NTX) [ Time Frame: Day 90 ]MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in urinary NTX at 90 days
- Serum osteocalcin [ Time Frame: Day 90 ]MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum osteocalcin at 90 days
- Serum bone alkaline phosphatase [ Time Frame: Day 90 ]MARKERS OF BONE FORMATION: change from Baseline (Day 0) in serum bone alkaline phosphatase at 90 days
- Serum amino-terminal pro-peptide of type 1 procollagen (P1NP) [ Time Frame: Day 90 ]MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum P1NP at 90 days
- Serum C-terminal telopeptide of type 1 collagen (CTX) [ Time Frame: Day 90 ]MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in serum CTX at 90 days

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy women
- Aged between 55 and 65 years
- Primary or secondary amenorrhea for at least 5 years
- BMI ≥ 20 kg/m2 and < 27 kg/m2
- DXA > 2.5 SD
- No history of fragility fracture bone
- Not under guardianship
- Not on hormone replacement or any osteoporotic therapy
- Covered by Social Security
- Negative serology for hepatitis B/C and HIV
- Written informed consent form signed.
Exclusion Criteria:
- Bone density < 2.5 SD (standard deviation)
- Endocrine disease
- No history of fragility fracture bone
- Dietary disorder (anorexia, bulimia)
- Hormone replacement therapy
- Inclusion in another clinical study
- Subjects receiving over 4,500 Euros in the last 12 months (including the present study)
- Subjects presenting risk of non-compliance in the opinion of the recruiting doctor.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01293045
France | |
CRNH - Centre de Recherche sur Volontaires - Hôpital AVICENNE | |
Bobigny, Seine-saint-denis, France, 93009 |
Principal Investigator: | Robert BENAMOUZIG, MD, PhD | Centre de Recherche en Nutrition Humaine d'Ile-de-France |
Responsible Party: | Nealth Sarl |
ClinicalTrials.gov Identifier: | NCT01293045 |
Other Study ID Numbers: |
ROU_COLHYD09 2009-A01217-50 ( Registry Identifier: AFSSAPS (France) ) |
First Posted: | February 10, 2011 Key Record Dates |
Last Update Posted: | April 9, 2014 |
Last Verified: | February 2011 |
Osteoporosis Postmenopausal women Functional food Hydrolysed collagen |
Bone metabolism Bone marker of resorption Bone marker of formation |
Osteoporosis Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Metabolic Diseases |